Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1516 • ACR Convergence 2025
The Benefits of SGLT2i on GFR Slope and Proteinuria in SLE Depend on Subgroups of Diabetes Mellitus and Baseline eGFR
Jennifer Lee¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) affects over 50% of SLE patients. Twenty percent of LN patients develop end-stage renal disease (ESRD) within 10 years. The 2021…
Abstract Number: 1534 • ACR Convergence 2025
Rapid Oral Glucocorticoid Discontinuation or Dose Reduction Among US Patients with SLE Receiving Belimumab in a Real-World Setting
Yan Chen¹, Maral DerSarkissian¹, Shumin Rui¹, Justin Clark¹, Daniel Moldaver², Jeffrey J. Ellis³, Karen Worley³ and Aarat M Patel⁴, ¹Analysis Group, Los Angeles, CA, ²GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, US Medical Affairs, Durham, NC
Background/Purpose: Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells that drive lupus disease activity, is approved…
Abstract Number: 1552 • ACR Convergence 2025
Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
Zahi Touma¹, Ian Bruce², Richard Furie³, Eric Morand⁴, Raj Tummala⁵, Shelly Chandran⁶, Gabriel Abreu⁷, Jacob Knagenhjelm⁷, Cathy Emmas⁸, Lyra Agustin⁸, Alessandra Venerus⁹, Tarana Mehdikhanova¹⁰, Zheyuan Yang¹⁰ and Miina Waratani⁸, ¹University of Toronto, Toronto, ON, Canada, ²Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁵AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, Gaithersburg, MD, ⁶AstraZeneca, Medical & Scientific Affairs, R&I, Mississauga, ON, Canada, ⁷AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden, ⁸AstraZeneca, BioPharmaceuticals Medical, Cambridge, United Kingdom, ⁹IQVIA, EMEA Real World Methods and Evidence Generation, Milan, Italy, ¹⁰IQVIA, EMEA Real World Methods and Evidence Generation, London, United Kingdom
Background/Purpose: Patients with systemic lupus erythematosus (SLE) can develop cardiovascular (CV) damage (angina, myocardial infarction, ventricular dysfunction, valvular disease, or pericarditis for 6 months/pericardiectomy) particularly…
Abstract Number: 1707 • ACR Convergence 2025
Racial and Ethnic Disparities in Kidney Transplant Outcomes Among Patients With Systemic Lupus Erythematosus (SLE): A 20-Year Analysis Spanning Before and After the 2014 Kidney Allocation System Revision
Soziema Salia¹, Boniface Mensah², Ufuoma Mamoh¹, Gilava Hedayati¹, Terrylyna Baffoe-Bonnie³, Joan Morny⁴ and Christhopher Haas³, ¹MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, MD, ²MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, CA, ³MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, ⁴Piedmont Athens Regional Internal Medicine Residency Program, Athens, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of end-stage kidney disease (ESKD) in young women, particularly among racial and ethnic minorities. Kidney transplantation…
Abstract Number: 1777 • ACR Convergence 2025
Granzyme B as a regulator of interferon alpha production in cutaneous lupus erythematosus
Touraj Khosravi¹, Ahmed Eldaboush², Darae Kang³ and Victoria Werth², ¹Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Potomac, MD
Background/Purpose: Recent studies have shown that monocytes, macrophages, and conventional DCs, but not plasmacytoid dendritic cells (pDC), are major sources of IFNα in cutaneous lupus…
Abstract Number: 1847 • ACR Convergence 2025
Spatial transcriptomics reveals a complex microanatomic patterning of complement mediated inflammation and fibrosis in Class III pediatric lupus nephritis associated with local histologic injury
Sarah McCuaig¹, Julia Rood¹, Em Elliott¹, Portia Kreiger¹ and Edward Behrens², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²CHOP, West Chester, PA
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of patients with pediatric systemic lupus erythematosus (pSLE) and results in significant morbidity due to suboptimal kidney…
Abstract Number: 1918 • ACR Convergence 2025
Vigorous Physical Activity in Patients with SLE Was Not Associated with Disease Activity or Socioeconomic and Social Factors
Heather Gold¹, Yi Li¹, Isabella Giunta¹, Jill Buyon¹, Peter Izmirly², Mala Masson³, Amit Saxena¹, H Michael Belmont⁴, Chung-E Tseng⁵ and Rebecca Anthopolos¹, ¹NYU Grossman School of Medicine, New York, NY, ²New York University Grossman School of Medicine, New York, NY, ³NYU Langone Health, New York, ⁴NYU School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, Flushing, NY
Background/Purpose: Physical activity can mitigate cardiovascular disease and depression risk and improve fatigue, physical function, and quality of life in patients with SLE. To facilitate…
Abstract Number: 2201 • ACR Convergence 2025
Adherence to Reproductive Health Guidelines in Lupus Care: Insights from Patient and Physician Surveys
Akhil Sood¹, Leanna Wise², Sadaf Sediqi¹, Alyssa Howren¹, Amanda Moyer¹, Ellie Diamond¹, Yashaar Chaichian³ and Julia F Simard⁴, ¹Stanford University, Palo Alto, CA, ²LAGMC/Keck Medicine of USC, Los Angeles, ³Stanford University, Stanford, CA, ⁴Stanford Medicine, Stanford, CA
Background/Purpose: The American College of Rheumatology has established guidelines for managing reproductive health in patients with rheumatic diseases. We assessed contraception use and counseling of…
Abstract Number: 2378 • ACR Convergence 2025
Factors Associated With Fatigue In Systemic Lupus Erythematosus: Data From The Almenara Lupus Cohort
Alvaro Oyarce-Calderón¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Samira Garcia-Hirsh⁴, Zoila Rodríguez-Bellido⁵, Cesar Pastor-Asurza⁶, Risto Perich-Campos⁷, Graciela Alarcón⁸ and Manuel Ugarte-Gil⁹, ¹Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁷Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁸The University of Alabama at Birmingham, Oakland, CA, ⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a wide spectrum of clinical manifestations, fatigue being one of them; it is…
Abstract Number: 2394 • ACR Convergence 2025
Impact of Immunosuppressive Regimens on Major Cardiac Events in Patients with Systemic Lupus Erythematosus (SLE): A Survival Analysis
Emily Cosentino¹, Melissa Akselrad², Niurka Liranzo Tejera², Christine Lenchur², Takemichi Matsui², Adal Abonamah², Priscilla Abate Namnum¹, Olga Marushchak², Martin John³, Sophia Lutgen⁴, Celestine He⁵, Boluwatito Oladeinde⁶, Harleen Sidhu⁷ and Chrisanna Dobrowolski⁵, ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, ²Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, ⁴Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York City, NY, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Icahn School of Medicine, New York, NY, ⁷Icahn School of Medicine at Mount Sinai/NYC H+H- Elmhurst, Queens, NY, Rego Park, NY
Background/Purpose: Cardiovascular events are a significant source of morbidity and mortality in SLE patients, occurring more frequently than in the general population owing to immune…
Abstract Number: 2412 • ACR Convergence 2025
Evolving Trends in Pulmonary Arterial Hypertension among Systemic Lupus Erythematosus Patients: A Nationwide Analysis
Maria Romero Noboa¹, Faria Sami², Almurtada Razok³ and Shahzad Ahmed Sami⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²The University of Alabama at Birmingham, Birmingham, AL, ³John H Stroger Jr Hospital of Cook County, Chicago, IL, ⁴DCH Regional Medical Center, Birmingham
Background/Purpose: Pulmonary arterial hypertension (PAH) is a rare manifestation of Systemic Lupus Erythematosus (SLE) with increased morbidity and mortality. It has historically been underdiagnosed in…
Abstract Number: 2431 • ACR Convergence 2025
Bone marrow- activity on 18F-FDG PET/CT as a Predictor of Hematologic Manifestations in Systemic Lupus Erythematosus
Sungwon Ko¹, Young-Eun Kim¹, Soyoon Yoon², Soo Min Ahn¹, Ji Seon Oh¹, Yong-Gil Kim¹, Chang-Keun Lee³, Bin Yoo¹, Dong Yun Lee⁴ and Seokchan Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, ²Department of Nuclear Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea, ³Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea, ⁴Department of Nuclear Medicine, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea
Background/Purpose: Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a noninvasive imaging modality widely used to assess inflammatory activity in various autoimmune and hematologic…
Abstract Number: 2448 • ACR Convergence 2025
Rituximab as the first line treatment in newly diagnosed systemic lupus erythematosus
Haiting Wang¹, Liling Zhao², Shuang Ye³ and Shaoying Yang², ¹Renji Hospital, Rockville, MD, ²Renji hospital, Shanghai, China (People's Republic), ³Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Rituximab (RTX) has been commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE), yet real-world data concerning RTX…
Abstract Number: 2466 • ACR Convergence 2025
Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis
Richard Furie¹, Neel Anand², Shraddha Desai³, Eric Lowe⁴, Tony Muchamuel³, Kiruthi Palaniswamy², Rachel Peterson², Kathryn Ray², Zung To², Jennifer Whang² and Richard Leff⁵, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Kezar Life Sciences, Inc, South San Francisco, CA, ³Kezar Life Sciences, Inc, South San Francisco, ⁴Kezar Life Sciences, South San Francisco, CA, ⁵Richard L Leff MD LLC, Chadds Ford, PA
Background/Purpose: Zetomipzomib (zeto), a selective immunoproteasome inhibitor, has previously shown anti-inflammatory activity in patients (pts) with SLE and LN in the open-label MISSION study. The…
Abstract Number: 2600 • ACR Convergence 2025
Deconstructing Lupus Nephritis Kidney Tissue at Single-Cell Resolution
Nicholas Sugiarto¹, Michelle Curtis², Siddarth Gurajala², Thomas Eisenhaure³, Qian Xiao⁴, Joseph Mears⁵, Arnon Arazi⁶, Paul Hoover⁷, Celine Berthier⁸, Saori Sakaue⁹, Andrea Fava¹⁰, David Hildeman¹¹, E. Steve Woodle¹², Brad Rovin¹³, Jennifer Barnas¹⁴, Maria Dall'Era¹⁵, Chaim Putterman¹⁶, Diane Kamen¹⁷, Maureen McMahon¹⁸, Jennifer Grossman¹⁹, Kenneth Kalunian²⁰, Jeffrey Hodgin²¹, Fernanda Payan Schober²², Mariko Ishimori²³, Michael Weisman²³, William Apruzzese²⁴, Joel Guthridge²⁵, Michael Brenner²⁶, Jennifer Anolik²⁷, David Wofsy²⁸, Judith James²⁵, Deepak Rao⁷, Anne Davidson²⁹, Michelle Petri³⁰, Jill Buyon³¹, Nir Hacohen³², Betty Diamond³³ and Soumya Raychaudhuri⁷, ¹Harvard Medical School, Brookline, MA, ²Harvard Medical School, Boston, ³Broad Institute, Cambridge, MA, ⁴Harvard Medical School, Boston, MA, ⁵Michigan University, Ann Arbor, MI, ⁶Feinstein Institutes for Medical Research, Acton, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Washington, Yokohama, Japan, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Cincinnati Children's Hospital, Cincinnati, OH, ¹²UC Health, Cincinnati, ¹³The Ohio State University, Columbus, OH, ¹⁴University of Rochester, Rochester, NY, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶Albert Einstein College of Medicine, Safed, Israel, ¹⁷Medical University of South Carolina, Johns Island, SC, ¹⁸UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁹UCLA, Sherman Oaks, CA, ²⁰UC San Diego, La Jolla, CA, ²¹University of Michigan, Ann Arbor, ²²TTUHSC, El Paso, TX, ²³Cedars-Sinai Medical Center, Los Angeles, CA, ²⁴Pfizer, Boston, ²⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁶Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²⁷University of Rochester Medical Center, Rochester, NY, ²⁸University of California San Francisco, SF, CA, ²⁹Feinstein Institutes for Medical Research, Manhasset, NY, ³⁰Johns Hopkins University School of Medicine, Timonium, MD, ³¹NYU Grossman School of Medicine, New York, NY, ³²Broad Institute of MIT Harvard, Cambridge, MA, ³³The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) is a heterogeneous disease driven by diverse immune and tissue cell types. We defined the cell states in the tissue and…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].